Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Protara Therapeutics will webcast its September 15, 2026 H.C. Wainwright conference presentation via the investor relations section of its website.

Rhea-AI Summary

Protara Therapeutics (TARA) will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET.

The live presentation webcast will be accessible through the Events and Presentations section of Protara’s investor relations website and will remain archived for a limited time. The company is a clinical-stage biotechnology developer of therapies for cancer and rare diseases, including lead candidate TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients on parenteral support.

Argus Sep 9 session

-1.54% close to close Open Argus

Details

News Market Reaction – TARA

On Sep 9, the first trading day after this news, TARA closed 1.54% below the previous close.

Data tracked by StockTitan Argus for the Sep 9 session.

Key Terms

non-muscle invasive bladder cancer, carcinoma in situ, parenteral support

3 terms

non-muscle invasive bladder cancer medical

"treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations"

A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.

carcinoma in situ medical

"NMIBC patients with carcinoma in situ (CIS)"

Carcinoma in situ is an early-stage abnormal growth where cells look cancerous but remain confined to the tissue surface and have not invaded deeper layers or spread to other parts of the body; think of it like graffiti on a wall that hasn’t cracked the plaster beneath. For investors, it matters because treatments, regulatory pathways, clinical trial outcomes and long-term costs differ greatly between contained lesions and invasive cancer, influencing market value, approval odds and liability for healthcare companies.

parenteral support medical

"patients on parenteral support who are otherwise unable"

Parenteral support is medical care that delivers nutrition, fluids or medications directly into a patient’s bloodstream or body tissues, bypassing the digestive system—think of it as feeding or hydrating someone through an IV rather than by mouth. Investors care because this service involves specialized products, durable revenue from long-term patient use, strict safety and reimbursement rules, and potential regulatory or supply risks that affect company earnings and growth.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET.

A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in ongoing clinical trials in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a pivotal Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors access Protara Therapeutics’ presentation at the H.C. Wainwright conference?

A live webcast of the September 15, 2026 Protara Therapeutics presentation can be accessed by visiting the Events and Presentations section of the company’s investor relations website at https://ir.protaratx.com. The webcast will be archived on the site for a limited time following the event.

What are the main clinical programs in Protara Therapeutics’ portfolio?

Protara’s portfolio includes its lead candidate TARA-002, an investigational cell-based therapy in development for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement being developed for patients on parenteral support who cannot meet choline needs via oral or enteral routes.

In which patient populations is TARA-002 currently being evaluated?

TARA-002 is being evaluated in ongoing clinical trials in non-muscle invasive bladder cancer patients with carcinoma in situ who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, and in a pivotal Phase 2 trial in pediatric patients with lymphatic malformations.